RGRX - RegeneRx Biopharmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.193
-0.007 (-3.50%)
At close: 3:55PM EDT
Stock chart is not supported by your current browser
Previous Close0.200
Open0.186
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.186 - 0.200
52 Week Range0.140 - 0.380
Volume12,905
Avg. Volume59,167
Market Cap23.09M
Beta2.16
PE Ratio (TTM)N/A
EPS (TTM)-0.006
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Trade prices are not sourced from all markets
  • PR Newswire20 days ago

    ReGenTree Presents Results of a Comparison Study of RGN-259 and Approved Prescription Drugs for Dry Eye Syndrome in a Mouse Model at ARVO

    ROCKVILLE, Md., May 2, 2018 /PRNewswire/ -- ReGenTree, LLC (the "Company"), a joint venture between GtreeBNT and RegeneRx Biopharmaceuticals (RGRX), announced today that the Company presented results of a comparison study of RGN-259 and marketed products for dry eye syndrome in a dry eye mouse model at ARVO (The Association for Research in Vision and Ophthalmology) meeting in Honolulu, Hawaii. Gabriel Sosne, M.D. at Wayne State University School of Medicine and Hynda Kleinman, Ph.D. at The George Washington University School of Medicine were among the authors of the study. The study found that RGN-259 treatment promoted recovery of mucins and goblet cells, improved corneal integrity, increased tears, and reduced inflammation in a dry eye mouse model.

  • PR Newswire27 days ago

    GtreeBNT Discloses Preliminary Observations from Seventeen NK Patients Treated with RGN-259 Eye Drops

    ROCKVILLE, Md. , April 25, 2018 /PRNewswire/ --  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on ...

  • PR Newswirelast month

    RegeneRx Announces Outcome of FDA Discussions for Development of RGN-259 for Dry Eye Syndrome

    ROCKVILLE, Md., April 9, 2018 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced the outcome of discussions between its U.S. joint venture, ReGenTree LLC, and the FDA regarding the results of the completed phase 3 clinical trial (ARISE-2) and the future development requirements for a New Drug Application ("NDA") submission of RGN-259, a novel drug candidate to treat dry eye syndrome. "Although the FDA is requiring an additional phase 3 trial (ARISE-3) to further demonstrate efficacy in both signs and symptoms of dry eye in a larger patient population, all safety data from ARISE-1 and ARISE-2 were accepted by the FDA, no additional nonclinical efficacy and safety studies are required by the FDA, and the Company's chemistry and manufacturing control plans for the drug substance and drug product were considered complete and acceptable for NDA submission.

  • PR Newswire2 months ago

    RegeneRx Receives Notice of Allowance of U.S. Patent for Treatment of Corneal Wounds

    Corneal wounds can occur from refractive surgeries such as Lasik, eye disorders such as diabetic keratopathy and dry eye syndrome, and traumatic injuries related to abrasions and burns.   Infections, as well as contact lenses, can also play a role in the development of corneal wounds.  A simple-to-use, safe and effective eye drop to treat such wounds would address a significant unmet medical need. RegeneRx has licensed the U.S. rights to RGN-259, currently in phase 3 clinical trials in the U.S., to ReGenTree, LLC, a joint venture between GtreeBNT and RegeneRx.  RegeneRx retains full ownership of the intellectual property and knowhow related to RGN-259 in the EU.

  • PR Newswire2 months ago

    RegeneRx Receives "Decision to Grant" European Patent For Treatment of Peripheral Neuropathy

    ROCKVILLE, Md. , March 12, 2018 /PRNewswire/ --  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on ...

  • PR Newswire3 months ago

    RegeneRx Secures $1 Million in Funding

    ROCKVILLE, Md., March 2, 2018 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it entered into a Warrant Reprice Agreement whereby it received $1.03 million in warrant exercise proceeds. The warrant exercise proceeds should fund current operations into 2019.

  • PR Newswire3 months ago

    Key U.S. Dry Eye Patent Issued to RegeneRx

    ROCKVILLE, Md. , Feb. 22, 2018 /PRNewswire/ --  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue ...

  • PR Newswire3 months ago

    RegeneRx Receives Canadian Patent for Treating Neurological Injury and Damage

    ROCKVILLE, Md. , Feb. 14, 2018 /PRNewswire/ --  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue ...

  • PR Newswire5 months ago

    RegeneRx Releases Annual Letter to Shareholders

    ROCKVILLE, Md., Dec. 7, 2017 /PRNewswire/ --RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its year end letter to shareholders. The letter is focused on updating shareholders on the Company's product development and commercial partnerships, clinical trials, fund-raising, and other operational plans over the next twelve months. Any statements in this shareholder letter that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995.

  • RegeneRx Biopharmaceuticals, Inc. :RGRX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
    Capital Cube6 months ago

    RegeneRx Biopharmaceuticals, Inc. :RGRX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017

    Categories: Yahoo FinanceGet free summary analysis RegeneRx Biopharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of RegeneRx Biopharmaceuticals, Inc. – MediWound Ltd., XOMA Corporation, Novartis AG Sponsored ADR, Akorn, Inc., Johnson & Johnson, Rigel Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc. Class A, Mateon Therapeutics, Inc. ... Read more (Read more...)

  • PR Newswire6 months ago

    Tβ4's Role in Treatment of Eye Diseases Showcased at 5th International Thymosin Symposium

    ROCKVILLE, Md., Nov. 16, 2017 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that Thymosin beta 4 (Tβ4), the active ingredient in RGN-259, a preservative-free ophthalmic eye drop, was the subject of a Keynote Address at the 5th International Symposium of Thymosins in Health and Disease in Washington, DC. The presentation was given by Dr. Gabriel Sosne, an award-winning clinician scientist, Associate Professor in Ophthalmology and Anatomy and Cell Biology at Wayne State University School of Medicine, and a clinician at the Kresge Eye Institute in Detroit, MI.  Dr. Sosne has spent over fifteen years studying the role of Tβ4 in ophthalmic diseases and treatment and is on the scientific advisory board of the Company.

  • RegeneRx Biopharmaceuticals, Inc. :RGRX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017
    Capital Cube8 months ago

    RegeneRx Biopharmaceuticals, Inc. :RGRX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017

    Categories: Yahoo FinanceGet free summary analysis RegeneRx Biopharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of RegeneRx Biopharmaceuticals, Inc. – MediWound Ltd., XOMA Corporation, Akorn, Inc., Mateon Therapeutics, Inc., Rigel Pharmaceuticals, Inc. and Sucampo Pharmaceuticals, Inc. Class A (MDWD-US, XOMA-US, AKRX-US, MATN-US, RIGL-US and ... Read more (Read more...)

  • PR Newswire8 months ago

    RegeneRx Receives Notice of Allowance for Key Dry Eye Patent in U.S.

    ROCKVILLE, Md. , Sept. 13, 2017 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue ...

  • PR Newswire9 months ago

    RegeneRx Completes License Expansion for RGN-137 in Europe, S. Korea, Japan, Canada and Australia

    ROCKVILLE, Md., Aug. 31, 2017 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has completed a license expansion agreement with GtreeBNT for the rights to RGN-137, RegeneRx's topical gel formulation of thymosin beta 4 (Tβ4), in Europe, S. Korea,  Japan, Canada and Australia. The financial terms of the agreement comprise three payments, including one upon signing and two subsequent additional payments over the next six months.  The agreement also includes milestone payments and royalties on commercial sales.  The terms are consistent with previous licenses between the two parties.  The Company will file non-confidential information related to the transaction on form 8-K.

  • PR Newswire9 months ago

    RegeneRx Announces Participation At The 19th Annual Rodman & Renshaw Global Investment Conference In New York September 10-12, 2017

    ROCKVILLE, Md., Aug. 30, 2017 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  The conference is being held on September 10-12, 2017 at Lotte New York Palace Hotel in New York City. If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link (www.rodmanevents.com) to register for the conference.  Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

  • PR Newswire9 months ago

    RegeneRx Collaborators Receive Notice of 'Intent to Grant' EU Patent for the Treatment of Peripheral Neuropathy

    Research Conducted Under Material Transfer Agreement Provides Potential Large Therapeutic Market Target for RGN-352 in the U.S. and EU ROCKVILLE, Md. , Aug. 14, 2017 /PRNewswire/ -- RegeneRx Biopharmaceuticals, ...

  • PR Newswire10 months ago

    RegeneRx Updates on RGN-259 Phase 3 Dry Eye Trial

    ROCKVILLE, Md., July 27, 2017 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its U.S. joint venture, ReGenTree LLC, has completed treatment of the last patient enrolled in its Phase 3 "ARISE-2" clinical trial testing RGN-259 preservative-free eye drops for dry eye syndrome ("DES"). ARISE-2 is a double-masked, placebo-controlled clinical trial that enrolled approximately 600 patients in the U.S. and was initiated less than 12 months ago. The trial is designed to replicate the clinical results achieved in ARISE-1, a Phase 2b/3 clinical trial in patients with DES.  Patient data will be scrubbed and validated prior to data lock and subsequent statistical analysis.  ReGenTree will report the results as soon as practicable thereafter.

  • PR Newswire11 months ago

    RegeneRx Collaborators Receive Notice of Allowance of U.S. Patent for the Treatment of Peripheral Neuropathy

    ROCKVILLE, Md. , June 13, 2017 /PRNewswire/ --  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue ...